Cargando…
A Multivalent and Thermostable Nanobody Neutralizing SARS-CoV-2 Omicron (B.1.1.529)
BACKGROUND: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants have risen to dominance, which contains far more mutations in the spike protein in comparison to previously reported variants, compromising the efficacy of most existing vaccines or therapeutic monoclonal a...
Autores principales: | Lu, Yuying, Li, Qianlin, Fan, Huahao, Liao, Conghui, Zhang, Jingsong, Hu, Huan, Yi, Huaimin, Peng, Yuanli, Lu, Jiahai, Chen, Zeliang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869787/ https://www.ncbi.nlm.nih.gov/pubmed/36700149 http://dx.doi.org/10.2147/IJN.S387160 |
Ejemplares similares
-
T Cell Activating Thermostable Self‐Assembly Nanoscaffold Tailored for Cellular Immunity Antigen Delivery
por: Zhang, Jinsong, et al.
Publicado: (2023) -
Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance
por: Chen, Jiahui, et al.
Publicado: (2021) -
The rapid replacement of the Delta variant by Omicron (B.1.1.529) in England
por: Paton, Robert S., et al.
Publicado: (2022) -
Vaccination and Transmission Risk during the Outbreak of B.1.1.529 (Omicron)
por: Grüne, Barbara, et al.
Publicado: (2022) -
Identifying susceptibility of children and adolescents to the Omicron variant (B.1.1.529)
por: Chun, June Young, et al.
Publicado: (2022)